New drug may spare transplant patients from lifelong immune suppression

NCT ID NCT05996627

Recruiting now Disease control Sponsor: Fred Hutchinson Cancer Center Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 21 times

Summary

This study tests whether the drug belumosudil can prevent chronic graft-versus-host disease (cGVHD), a common complication after stem cell transplants where the donor's immune cells attack the patient's body. About 82 participants will receive either belumosudil or a placebo. The goal is to see if the drug can delay or avoid the need for additional immune-suppressing medications, which often have serious side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Dana-Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States

Contact
Fred Hutch/University of Washington Cancer Consortium
RECRUITING

Seattle, Washington, 98109, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States

Contact
Moffitt Cancer Center
RECRUITING

Tampa, Florida, 33612, United States

Contact

Conditions

Explore the condition pages connected to this study.

CHRONIC GRAFT VERSUS HOST DISEASE